BioJiva
Private Company
Funding information not available
Overview
BioJiva is a private, clinical-stage biotech targeting the root cause of degenerative diseases through its novel platform of isotopically stabilized, oxidation-resistant PUFAs. The company's lead candidate, BRX011, is an orally administered, deuterated version of docosahexaenoic acid (DHA) being developed for geographic atrophy (GA) secondary to age-related macular degeneration, a leading cause of blindness with high unmet need. With a strong scientific foundation evidenced by extensive cited literature, BioJiva is positioned to address a key pathological driver in AMD and potentially other conditions linked to lipid peroxidation, though it faces the typical risks of an early-stage drug developer.
Technology Platform
Platform for designing and synthesizing isotopically stabilized (e.g., deuterated), oxidation-resistant polyunsaturated fatty acids (PUFAs) that replace natural PUFAs in cell membranes to inhibit lipid peroxidation and its toxic downstream effects.
Opportunities
Risk Factors
Competitive Landscape
In geographic atrophy (GA), BioJiva faces competition from approved complement C3 inhibitors (Syfovre, Izervay) and other late-stage pipeline candidates. Its key differentiator is the oral route of administration and an upstream, root-cause mechanism targeting lipid peroxidation, rather than downstream complement inhibition. However, it must demonstrate superior or comparable efficacy to established injectable standards of care.